Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CA-4948 |
Synonyms | |
Therapy Description |
CA-4948 inhibits IRAK4, thereby blocking TLR and IL-1R signaling, potentially resulting in tumor regression (PMID: 33335659). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CA-4948 | CA4948|CA 4948|Emavusertib|AU 4948|AU4948|AU-4948 | IRAK4 Inhibitor 7 | CA-4948 inhibits IRAK4, thereby blocking TLR and IL-1R signaling, potentially resulting in tumor regression (PMID: 33335659). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04278768 | Phase I | CA-4948 | An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Recruiting | USA | POL | ITA | ISR | FRA | ESP | DEU | CZE | 0 |
NCT03328078 | Phase I | CA-4948 | A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | POL | ITA | ISR | FRA | ESP | CZE | 0 |
NCT05178342 | Phase II | CA-4948 | Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS) | Terminated | DEU | 0 |